COPD Management

with the AGM100®

The AGM100® provides an objective measure of pulmonary gas exchange in COPD patients.

The AGM100® is a powerful clinical tool. Designed with clinicians in mind, it is lightweight, portable, and non-invasive. Coupled with an average two minute turnaround time for results, the AGM100® is ideal for assessing gas exchange inefficiency.

With the AGM100® there is no need to coach patients through complicated maneuvers. 

COPD Screening

The AGM100® provides a fast objective measure of pulmonary gas exchange efficiency (inefficiency in sick patients) for quick detection of patients who should undergo a more intensive workup. Approx. 33 million Americans suffer from chronic or acute respiratory illness. COPD is the third leading cause of death, according to The American Lung Association. Proper screening and early intervention can greatly improve the prognosis for COPD patients. 

Monitoring Progression

Effectively monitor a patient’s disease progression by establishing a baseline Oxygen Deficit level with the MediPines Gas Exchange monitor (AGM100®). Oxygen Deficit is a highly sensitive measurement of gas exchange efficiency. Obtained from a patient’s normal breathing, the AGM100® does not require the patient to perform any special maneuvers. The device is cost-effective, easy to use, and designed for taking point-of-care measurements in under two minutes.

Treatment Response

Rapidly evaluate a patient’s response to treatment using Oxygen Deficit. Oxygen Deficit is an objective measure that indicates the degree of gas exchange efficiency in the lungs. Oxygen Deficit is only available on the MediPines Gas Exchange monitor, the AGM100®.  This fast, repeatable, and objective measure of gas exchange efficiency finally makes routine evaluation of treatment response practical and time efficient. Oxygen Deficit results in one to two minutes.

The COPD Foundation recently published a study about the readmission rates of patients with COPD. “After discharge, 10% to 20% of COPD patients are readmitted within 30 days.10,11 Patients who are readmitted following a COPD hospitalization are at greater risk of mortality and have worse outcomes relative to patients who are not readmitted.12 A number of interventions have been proposed to reduce readmissions.13 However, these interventions have not shown a reduction in readmissions and mortality.13 One reason may be the inability to identify patients at the greatest risk of readmission and to target resources to these high-risk patients.”*

* https://journal.copdfoundation.org/jcopdf/id/1125/Identifying-Patients-With-COPD-at-High-Risk-of-Readmission

The MediPines Gas Exchange Monitor (AGM100®) is a non-invasive, multi-parameter respiratory monitoring device that provides spot-check respiratory gas measurements. The AGM100® is indicated for use in various clinical settings under clinicians’ judgement (professional healthcare facilities) when assessment of gas exchange status is required on conscious and cooperative adult patients. The AGM100® is not to be utilized simultaneously with supplemental oxygen nor with other respiratory gases or agents.  It is not intended to be used as the sole basis for making diagnosis or treatment decisions related to patient gas exchange; it is intended to be used in conjunction with additional methods of assessing clinical signs and symptoms. It is not intended to replace arterial blood gas sampling for diagnosis or treatment purposes.

The lack of an objective measure of pulmonary gas exchange can lead to unnecessary hospital admissions that have the potential to result in across-the0board penalization of government payer reimbursement.   Hospitals face up to a 3% loss of total Medicare reimbursement if their readmission rates are beyond the standards set for that year. The MediPines Gas Exchange Monitor® provides clinicians with an objective repeatable measure of gas exchange efficiency. The AGM100® is a tool that could drastically benefit the hospital in determining whether a patients’ Oxygen Deficit has reached an acceptable,* non-exacerbated level.

* Acceptable levels are determined by individual hospital clinical standards.